Nakata Tomoaki, Hashimoto Akiyoshi, Sugawara Hirohito
Department of Cardiology, Hakodate Goryoukaku Hospital, Goryoukaku-cho 38-3, Hakodate, 040-8611, Hokkaido, Japan,
Curr Heart Fail Rep. 2013 Dec;10(4):359-64. doi: 10.1007/s11897-013-0161-9.
The autonomic nervous system has pivotal roles in pathophysiology and prognosis in patients with heart failure. Cardiac (123)I-labeled metaiodobenzylguanidine (MIBG) imaging enables noninvasive and quantitative assessment of cardiac sympathetic innervation in cardiology practice. Several investigations have demonstrated independent and incremental prognostic values of this imaging technique in combination with clinical information in patients with heart failure. Cardiac MIBG imaging may help cardiologists evaluate cardiac sympathetic nerve function and predict lethal event risk in heart failure. It can contribute not only to the identification of low-risk or high-risk probability for lethal events but also to the selection of the appropriate therapeutic strategy, such as medical and device therapy in patients at greater risk for lethal outcomes due to pump failure or sudden arrhythmic events. Thus, precise risk stratification through cardiac MIBG imaging may contribute to more effective use of medical resources and more appropriate selection of therapeutic strategy in heart failure patients.
自主神经系统在心力衰竭患者的病理生理学和预后中起着关键作用。心脏（123）I标记的间碘苄胍（MIBG）显像能够在心脏病学实践中对心脏交感神经支配进行无创性定量评估。多项研究表明，这种显像技术与心力衰竭患者的临床信息相结合具有独立且递增的预后价值。心脏MIBG显像有助于心脏病学家评估心脏交感神经功能，并预测心力衰竭患者发生致命事件的风险。它不仅有助于识别致命事件的低风险或高风险概率，还有助于选择合适的治疗策略，例如对于因泵衰竭或突然心律失常事件而有更高致命结局风险的患者进行药物和器械治疗。因此，通过心脏MIBG显像进行精确的风险分层可能有助于更有效地利用医疗资源，并在心力衰竭患者中更恰当地选择治疗策略。
